RE:RE:RE:Licensing agreement?There have been previous slides in presentations which indicate a graph showing equipment scale and equipment grade. My interpretation is that there is some natural overlap between capacity and product status. Clinical study material starts at 10L to 50L and a commercial plant capacity starts at 50L to 100L. There is also a PGX development and milestone slide that Gilles discussed in the HCW Sept. 2022 webcast where he indicated that by the beginning of 2024 they can enter the market as there would be capacity for commercial quantities of energy/immune boosters at the rate of 2 - 4 million doses corresponding to 50L to 100L production capacity.
That's the general timeline. If the engineering firms are still working on design and with the plant location now selected, perhaps a firmer timeline and final costs can be given later. If I recall, a 50L plant can be supported by internal funds.
Stinzo wrote: Must be something about company culture that I do not understand ...
you announce the licensing of some spaces for scale up but do not provide any idea of cost and timing? For a company that moves quiet slowly, you would expect them to have all this information on hand by now, they have been studying this scale up for 12-24 months?
The way I read the article, is that only once this new 5-10 x demo plant is built will they be able to test products for future possible partnerships ...
I guess the market is acting like I am, very confused ... just waiting for Q3 results really at this point.